Key Takeaways Tvardi Therapeutics stock tumbled 83.9% after disappointing preliminary phase II REVERT IPF study data.TTI-101 failed to show meaningful improvement in lung function or efficacy compared with placebo.High discontinuation rates and gastrointestinal side effects in TTI-101 arms weighed on study outcomes.Shares of Tvardi Therapeutics (TVRD) nosedived 83.9% on Monday after the company provided a disappointing update following an analysis of preliminary data from a mid-stage study of its lead inves ...